Brief: Arvinas, Pfizer Announce Updated Clinical Data From Phase 1B Trial Of Vepdegestrant In Combination With Palbociclib
16/05/2024 11:12
May 16 (Reuters) - Arvinas Inc ARVN.O :
* ARVINAS AND PFIZER ANNOUNCE UPDATED CLINICAL DATA FROM
PHASE 1B
TRIAL OF VEPDEGESTRANT IN COMBINATION WITH PALBOCICLIB
(IBRANCE®)
* ARVINAS: AT RECOMMENDED PHASE 3 DOSE OF 200 MG
VEPDEGESTRANT
PLUS PALBOCICLIB, PATIENTS ACHIEVED A MEDIAN PROGRESSION-FREE
SURVIVAL OF 13.9 MONTHS
* ARVINAS INC: SAFETY PROFILE OF VEPDEGESTRANT IN
COMBINATION WITH
PALBOCICLIB WERE CONSISTENT WITH DATA PREVIOUSLY REPORTED AT
SABCS IN DEC
Source text for Eikon: ID:nGNX4vvnQp
Further company coverage: ARVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology